1. Generics Bulletin
  2. >>Business
  3. >>Manufacturing

Manufacturing Round-Up: Sterling Gains A US Site As Normon Invests €100m

 
• By Dave Wallace

Sterling Pharma Solutions has acquired a US facility and Olon has bought a plant from Sandoz, while Normon is investing €100m in manufacturing expansions.

Work station
• Source: Shutterstock

UK-based contract development and manufacturing organization (CDMO) Sterling Pharma Solutions has acquired CiVentiChem’s US facility in Cary, North Carolina. This “will allow Sterling to offer a local presence to its US clients and enhance its chemistry development capabilities to support pre-clinical and early-phase clinical supply”. Sterling’s CEO, Kevin Cook, said “we have been keen to expand our presence in the US market and the site’s capabilities complement our current service offering,” noting that the North American market accounted for “70% of our customer portfolio.”

Italian active pharmaceutical ingredient (API) specialist Olon has closed its acquisition of a former Sandoz manufacturing facility in Mahad, India

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

During the “CEOs Unplugged” panel at the AAM’s annual conference in February, leaders from Sandoz, Lupin and Amneal discussed the various ways in which the US framework is making life difficult for generics and biosimilars.

As US Launches Pharma Probe, AAM Warns Tariffs ‘Will Only Amplify Problems’

 
• By Dave Wallace

News of a fresh US investigation into the pharma sector has sparked renewed concerns over the impact that US trade tariffs would have on the generics and biosimilars industry. The AAM has responded with a warning over the potential effects on shortages and access, while Medicines for Europe has proposed five key action areas to bolster the sector in Europe.

Who’s Hired? Alvotech Appoints Strategy And Quality Chiefs

 
• By Dave Wallace

Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.